scPharmaceuticals (NASDAQ:SCPH - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.05, Zacks reports. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. The company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.08 million.
scPharmaceuticals Price Performance
Shares of scPharmaceuticals stock traded down $0.01 on Friday, hitting $3.00. The company had a trading volume of 571,430 shares, compared to its average volume of 325,319. The business has a 50-day simple moving average of $3.27 and a 200-day simple moving average of $3.78. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The company has a market cap of $150.85 million, a PE ratio of -1.58 and a beta of 0.40. scPharmaceuticals has a 52 week low of $2.75 and a 52 week high of $5.65.
Analyst Upgrades and Downgrades
SCPH has been the topic of several analyst reports. Maxim Group dropped their price target on shares of scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating on the stock in a research note on Thursday. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of scPharmaceuticals in a research note on Thursday.
View Our Latest Analysis on SCPH
scPharmaceuticals Company Profile
(
Get Free Report)
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
Further Reading
Before you consider scPharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and scPharmaceuticals wasn't on the list.
While scPharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
